FRANKFURT (Reuters) - Germany's Merck KGaA said in Monday it struck an alliance over cancer immunotherapy drugs with Pfizer , triggering an upfront payment of $850 million by the U.S. drugmaker. The two companies will develop Merck's so-called anti-PD-L1 agent as a single therapy as well as in combinations with Pfizer's and Merck's portfolio of approved and experimental drug candidates. Apart from the upfront payment, Merck is eligible to receive regulatory and commercial milestone payments of up to $2 billion. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment